Protecadin

Protecadin is an emerging biotechnology company focused on the development of targeted protein degradation therapies. The company utilizes its proprietary platform to design and optimize Proteolysis Targeting Chimeras (PROTACs) that leverage the body's natural protein disposal system to eliminate disease-causing proteins. By targeting specific proteins that were previously considered undruggable, Protecadin aims to provide novel treatment options for patients with various forms of cancer and inflammatory diseases. The company's research is centered on improving the selectivity and potency of protein degraders to minimize off-target effects and enhance therapeutic efficacy.